Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
Day One Biopharmaceuticals reported insider trading activity for Michael Vasconcelles, Head of Research and Development, who received significant equity compensation on June 16, 2025:
- Stock Options: Granted 346,000 options to purchase common stock at $6.64 per share, vesting over 4 years (25% after first year, then monthly)
- Restricted Stock Units (RSUs): Awarded 226,000 RSUs with zero exercise price, vesting over approximately 4 years (25% in August 2026, remaining quarterly)
The equity grants suggest a long-term retention strategy for this key executive, with the options expiring June 15, 2035. The combined award of performance-based options and time-vested RSUs represents a significant compensation package aimed at aligning the executive's interests with shareholders while providing both upside potential and guaranteed value through RSUs.
Day One Biopharmaceuticals (DAWN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Michael Vasconcelles, who has joined the company as Head of Research and Development. The filing date is June 28, 2025, with the triggering event occurring on June 16, 2025.
Key details of the filing:
- The reporting person currently owns no securities (derivative or non-derivative) of the company
- The filing is made individually, not as part of a group
- The reporting person serves as an Officer (Head of Research and Development) but is not a Director or 10% Owner
- The form was signed by Charles N. York II as Attorney-in-Fact on June 18, 2025
This Form 3 filing is a standard regulatory requirement for new officers under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transactions and holdings reporting.